迈博药业-B(02181.HK) 公布,公司管线产品CMAB807普博力(地舒单抗注射液)的上市注册申请已获国家药监局批准,用于治疗骨折高风险的绝经后妇女的骨质疏松症;骨折高风险的男性骨质疏松症;及骨折高风险的糖皮质激素诱导的骨质疏松症。(ha/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻
Source Link迈博药业-B(02181.HK) 公布,公司管线产品CMAB807普博力(地舒单抗注射液)的上市注册申请已获国家药监局批准,用于治疗骨折高风险的绝经后妇女的骨质疏松症;骨折高风险的男性骨质疏松症;及骨折高风险的糖皮质激素诱导的骨质疏松症。(ha/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.